Fujisawa Pharmaceutical Company, Ltd.

Astellas Pharma Gmbh

Yoshiko Ueda

Keizo Yoshida

Kiyotaka Katsuta

Hajime Nakanishi

Hiroyuki Takamatsu

Masakazu Kobayashi

Yoshimasa Saito

Hisashi Yamada

Kouichi Tamura

Yoko Takata

Tatsuo Yamashita

This invention relates to a hematopoietic stem cell proliferating agent comprising IGF-I, a hematopoietic stem cell proliferating agent comprising IGF-I and at least one protein selected from among SCF, M-CSF, and G-CSF, and a method of growing hematopoietic stem cells which comprises culturing hematopoietic stem cells in a medium containing IGF-I and at least one protein selected from the group consisting of SCF and M-CSF. The hematopoietic stem cell proliferating agent of the invention causes hematopoietic stem cells to proliferate in the undifferentiated state whether in vivo or in vitro and can, therefore, be used for amelioration of the cytopenia induced by radiotherapy or chemotherapy using anticancer drugs, prevention of infectious diseases associated with lymphopenia, or in vitro culture for multiplication of hematopoietic stem cells and extrasomatic culture of recombinant stem cells in gene therapy.

Hematopoietic stem cell proliferating agents

Compounds for treating or preventing cerebrovascular diseases are disclosed. These compounds are 5-HT antagonists. More specifically, these compounds, when combined with pharmaceutically acceptable carriers or excipients and administered to animals including humans, are useful in treating or preventing cerebrovascular dementia.

Medicament for treating or preventing cerebrovascular dementia

Medicament for treating or preventing cerebrovascular infarction

Growing community of inventors

Osaka, Japan

Yoshiko Ueda